Cingulate (NASDAQ:CING) Now Covered by Analysts at Roth Mkm

Roth Mkm started coverage on shares of Cingulate (NASDAQ:CING) in a research report released on Friday, Marketbeat.com reports. The firm issued a buy rating and a $12.00 price target on the stock.

Separately, Maxim Group raised shares of Cingulate from a “hold” rating to a “buy” rating in a research report on Wednesday, November 20th.

Cingulate Stock Up 11.6 %

Shares of CING opened at $4.81 on Friday. The firm’s fifty day simple moving average is $4.36 and its two-hundred day simple moving average is $4.15. Cingulate has a 12 month low of $1.80 and a 12 month high of $88.44.

Cingulate (NASDAQ:CING) last announced its earnings results on Thursday, November 7th. The company reported ($1.83) EPS for the quarter, beating the consensus estimate of ($2.22) by $0.39. On average, equities research analysts predict that Cingulate will post -9.26 earnings per share for the current year.

Institutional Investors Weigh In On Cingulate

An institutional investor recently bought a new position in Cingulate stock. Armistice Capital LLC purchased a new stake in shares of Cingulate Inc. (NASDAQ:CING) in the second quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 490,000 shares of the company’s stock, valued at approximately $157,000. Armistice Capital LLC owned approximately 6.67% of Cingulate at the end of the most recent quarter. Institutional investors and hedge funds own 41.31% of the company’s stock.

About Cingulate

Cingulate Inc, a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company’s stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults.